Rani Therapeutics reported contract revenue of $5.1 million for the nine months ended September 30, 2026, a significant increase from $0.2 million in the prior year. Despite the revenue growth, the company recorded a net loss as total operating expenses reached $31.5 million, driven by increased research and development activities.
Rani Therapeutics reported third quarter 2026 financial results and announced its acceptance into the FDA’s Emerging Technology Program to support the RaniPill platform. The company reported a cash position of $45.3 million, which it expects will fund operations through the end of 2027, and noted that enrollment continues for its RT-114 Phase 1a expansion cohort.
“The third quarter marked continued progress for the RaniPill® platform and, most recently, our acceptance into the FDA’s Emerging Technology Program in October provides an opportunity to engage with the Agency on technical, manufacturing and regulatory considerations related to the RaniPill® platform.”
Talat Imran, Chief Executive Officer of Rani Therapeutics
“With cash, cash equivalents and marketable securities of $45.3 million, we believe we are well positioned to fund operations at least through the end of 2027 and to execute on our priorities, including additional RT-114 data by year-end.”
Talat Imran, Chief Executive Officer of Rani Therapeutics